Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Since it is not clear whether testosterone or dihydrotestosterone is the active hormone in bone metabolism, we wished to assess the effect of finasteride, a 5α‐reductase inhibitor, on vertebral bone mineral density and parameters of bone and mineral metabolism. DESIGN Patients were treated in a randomized, double‐blind controlled study with either placebo, 1 or 5 mg/day finasteride. PATIENTS Twenty‐three men with benign prostatic hyper‐plasla (BPH) were included in this study; eight received placebo, seven were allocated to treatment with 1 mg/day, and eight to 5 mg/day finasteride for 12 months. MEASUREMENTS Vertebral bone mineral density was measured at the lumbar spine by dual energy X‐ray bone densltometry. Serum calcium, phosphorus, parathyroid hormone, osteocalcln and vitamin D metabolites were measured regularly. Urinary calcium and creatinlne excretion were monitored as well. RESULTS Finasteride caused a significant decrease in serum dlhydrotestosterone after 6 and 12 months, but no effect on serum testosterone. Vertebral bone mineral density remained unaltered. None of the other parameters monitored were affected except for a small unexplained increase in 1,25‐dihydroxyvitamin D in the group receiving 5 mg finasteride/day. CONCLUSIONS Testosterone is probably the active hormone in bone metabolism. However, oestradiol, the product of testosterone aromatization (which remains unaltered under finasteride) may yet be another possible responsible steroid in the maintenance of bone density. We can also not rule out that the small amount of dihydrotestosterone remaining under finasteride administration is sufficient for maintaining normal bone metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dihydrotestosterone Formation in Fetal Tissues of the Rabbit and Rat
WILSON, J. D., & LASNITZKI, I. (1971) · Endocrinology · doi:10.1210/endo-89-3-659 · Cited by 173
Meier, D. E., Orwoll, E. S., Keenan, E. J., & Fagerstrom, R. M. (1987) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1987.tb02308.x · Cited by 131
Cited by
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717
“Finasteride, a type II 5 -reductase inhibitor, does not decrease vertebral bone density (388) or increase bone turnover markers (35) in men suffering from benign prostate hyperplasia, according to two small-sized short-term studies.”
BackgroundManolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517
Compston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 511
Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475
Amory, J. K., Wang, C., Swerdloff, R. S., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., Walker, S. E., Haberer, L. J., & Clark, R. V. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2203 · Cited by 244
Metadata
- Authors
- Matzkin, H., Chen, J., Weisman, Y., Goldray, D., Pappas, F., Jaccard, N., & Braf, Z.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 1992-11
- Volume
- 37
- Issue
- 5
- Pages
- 432-436
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2002816589
- Cited by
- 54
- References
- 2
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism. https://app.cochat.ai/papers/10.1111/j.1365-2265.1992.tb02355.x
- The paper
- Matzkin, H., Chen, J., Weisman, Y., Goldray, D., Pappas, F., Jaccard, N., & Braf, Z. (1992). Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.1992.tb02355.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.